ArifHussainMD

Oncology • Baltimore, MD

Professor, Medicine, University of Maryland School of Medicine

Join to view full profile

Dr. Hussain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hussain's full profile

Already have an account?

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-2567

Fax+1 410-328-6896

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1983 - 1986
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 1980 - 1983
Howard University College of MedicineClass of 1980

Certifications & Licensure

MD State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2000 May 01
Completed
Phase 2
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 3
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 1
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels Start of enrollment: 2016 Jan 01
Terminated
1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2019 Dec 12
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men.
Joseph Boyle, Jessica Yau, Jimmie L Slade, Derrick A Butts, Jessica Wimbush
Cancer Epidemiology, Biomarkers & Prevention. 2024-10-02
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
Majid Pornour, Hee-Young Jeon, Hyunju Ryu, Sudeep Khadka, Rui Xu
Proceedings of the National Academy of Sciences of the United States of America. 2024-07-30
2 citations
Neighborhood Disadvantage and Prostate Tumor RNA Expression of Stress-Related Genes.
Joseph Boyle, Jessica Yau, Jimmie L Slade, Derrick A Butts, Yuji Zhang
JAMA Network Open. 2024-07-01

Other

Chemotherapy in castrate-resistant prostate cancer
Hussain A, Dawson NA
http://www.uptodate.com/contents/chemotherapy-in-castrate-resistant-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-01-21

Professional Memberships

American Society of Clinical Oncology - ASCO
Member